文献速递中药与中成药合理使用

深绿卷柏提取物对人细胞色素P450酶的抑制作用

Inhibitory effect of Selaginella doederleinii hieron on human cytochrome P450.
PubMed 文献 · Front Pharmacol · 2023-02-15

本研究采用LC-MS/MS法建立的CYP450鸡尾酒探针法,检测深绿卷柏乙酸乙酯提取物(SDEA)及其四种成分对七种CYP450亚型的抑制潜力。结果显示SDEA对CYP2C9和CYP2C8有强抑制作用(IC50约1 μg/ml),对CYP2C19、CYP2E1和CYP3A有中等抑制作用(IC50<10 μg/ml);其中穗花杉双黄酮含量最高(13.65%)且抑制作用最强(IC50<5 μM)。提示SDEA或穗花杉双黄酮与临床药物联用时需考虑潜在草药-药物相互作用,而Delicaflavone对CYP450抑制不明显,更适于开发为临床药物。

要点

  • SDEA对CYP2C9和CYP2C8有强抑制作用,IC50约1 μg/ml。
  • 穗花杉双黄酮是SDEA抑制CYP450的主要成分,含量13.65%。
  • Delicaflavone对CYP450无明显抑制作用,更适合药物开发。

核心结论

  • 穗花杉双黄酮可能是SDEA抑制CYP450酶的主要原因,SDEA或穗花杉双黄酮与临床药物联用时应考虑潜在HDI。
  • Delicaflavone对CYP450代谢抑制水平低,更适合开发为临床药物。

研究设计与样本

  • 采用基于LC-MS/MS建立的CYP450鸡尾酒探针法,测试SDEA及其四种成分对七种CYP450亚型的抑制潜力。
  • 测定了SDEA中四种成分(穗花杉双黄酮、巴马汀、芹菜素、Delicaflavone)的含量。

主要发现

  • SDEA对CYP2C9和CYP2C8有强抑制作用(IC50≈1 μg/ml),对CYP2C19、CYP2E1和CYP3A有中等抑制作用(IC50<10 μg/ml)。
  • 穗花杉双黄酮在提取物中含量最高(13.65%),抑制作用最强(IC50<5 μM),尤其对CYP2C9、CYP2C8和CYP3A。
  • 穗花杉双黄酮对CYP2C19和CYP2D6显示时间依赖性抑制。
  • 芹菜素和巴马汀均显示浓度依赖性抑制;芹菜素抑制CYP1A2、CYP2C8、CYP2C9、CYP2E1和CYP3A,巴马汀抑制CYP3A并对CYP2E1有弱抑制作用。
  • Delicaflavone对CYP450酶无明显抑制作用。

临床怎么用

  • 使用SDEA或穗花杉双黄酮时,应评估与CYP2C9、CYP2C8底物药物的潜在相互作用。
  • Delicaflavone因对CYP450抑制低,可优先考虑作为抗癌药物开发候选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction: Selaginella doederleinii Hieron is a traditional Chinese herbal medicine, the ethyl acetate extract from Selaginella doederleinii (SDEA) showed favorable anticancer potentials. However, the effect of SDEA on human cytochrome P450 enzymes (CYP450) remains unclear. To predict the herb-drug interaction (HDI) and lay the groundwork for further clinical trials, the inhibitory effect of SDEA and its four constituents (Amentoflavone, Palmatine, Apigenin, Delicaflavone) on seven CYP450 isoforms were investigated by using the established CYP450 cocktail assay based on LC-MS/MS. Methods: Appropriate substrates for seven tested CYP450 isoforms were selected to establish a reliable cocktail CYP450 assay based on LC-MS/MS. The contents of four constituents (Amentoflavone, Palmatine, Apigenin, Delicaflavone) in SDEA were determined as well. Then, the validated CYP450 cocktail assay was applied to test the inhibitory potential of SDEA and four constituents on CYP450 isoforms. Results: SDEA showed strong inhibitory effect on CYP2C9 and CYP2C8 (IC50 ≈ 1 μg/ml), moderate inhibitory effect against CYP2C19, CYP2E1 and CYP3A (IC50 < 10 μg/ml). Among the four constituents, Amentoflavone had the highest content in the extract (13.65%) and strongest inhibitory effect (IC50 < 5 μM), especially for CYP2C9, CYP2C8 and CYP3A. Amentoflavone also showed time-dependent inhibition on CYP2C19 and CYP2D6. Apigenin and Palmatine both showed concentration-dependent inhibition. Apigenin inhibited CYP1A2, CYP2C8, CYP2C9, CYP2E1 and CYP3A. Palmatine inhibited CYP3A and had a weak inhibitory effect on CYP2E1. As for Delicaflavone, which has the potential to develop as an anti-cancer agent, showed no obvious inhibitory effect on CYP450 enzymes. Conclusion: Amentoflavone may be one of the main reasons for the inhibition of SDEA on CYP450 enzymes, the potential HDI should be considered when SDEA or Amentoflavone were used with other clinical drugs. On the contrast, Delicaflavone is more suitable to develop as a drug for clinical use, considering the low level of CYP450 metabolic inhibition.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Lin F, Lin X, Wang X, et al. Inhibitory effect of Selaginella doederleinii hieron on human cytochrome P450. Front Pharmacol. 2023. PMID: 36874034. doi:10.3389/fphar.2023.1108867

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。